6[7]De Bruyn Rossini AJ,Chiu YL,et al.Safety profile of recombinant canarypox HIV vaccinesHIV.Vaccines Trials Network Core Operations,Fred Hutchinson Cancer Research Center[J].Vaccine,2004,22(5-6):704.
7[8]Lee D,Graham BSC,hiu YL,et al.Breakthrough infections during phase 1 and 2 rime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of rexinbinant gp120or gpl60[J].Jinfect dis,2004,190(5):903.